Here's how LINK.SPRINGER.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

LINK . SPRINGER . COM {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Link.springer.com Make Money
  6. Keywords
  7. Topics
  8. Questions
  9. Schema
  10. External Links
  11. Analytics And Tracking
  12. Libraries
  13. CDN Services

We are analyzing https://link.springer.com/article/10.1186/s40425-015-0055-3.

Title:
Survival with AGS-003, an autologous dendritic cell–based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results | Journal for ImmunoTherapy of Cancer
Description:
AGS-003 is an autologous immunotherapy prepared from fully matured and optimized monocyte-derived dendritic cells, which are co-electroporated with amplified tumor RNA plus synthetic CD40L RNA. AGS-003 was evaluated in combination with sunitinib in an open label phase 2 study in intermediate and poor risk, treatment naïve patients with metastatic clear cell renal cell carcinoma (mRCC). Twenty-one intermediate and poor risk patients were treated continuously with sunitinib (4 weeks on, 2 weeks off per 6 week cycle). After completion of the first cycle of sunitinib, patients were treated with AGS-003 every 3 weeks for 5 doses, then every 12 weeks until progression or end of study. The primary endpoint was to determine the complete response rate. Secondary endpoints included clinical benefit, safety, progression free survival (PFS) and overall survival (OS). Immunologic response was also monitored. Thirteen patients (62%) experienced clinical benefit (9 partial responses, 4 with stable disease); however there were no complete responses in this group of intermediate and poor risk mRCC patients and enrollment was terminated early. Median PFS from registration was 11.2 months (95% CI 6.0, 19.4) and the median OS from registration was 30.2 months (95% CI 9.4, 57.1) for all patients. Seven (33%) patients survived for at least 4.5 years, while five (24%) survived for more than 5 years, including 2 patients who remain progression-free with durable responses for more than 5 years at the time of this report. AGS-003 was well tolerated with only mild injection-site reactions. The most common adverse events were related to expected toxicity from sunitinib therapy. In patients who had sequential samples available for immune monitoring, the magnitude of the increase in the absolute number of CD8+ CD28+ CD45RA− effector/memory T cells (CTLs) after 5 doses of AGS-003 relative to baseline, correlated with overall survival. AGS-003 in combination with sunitinib was well tolerated and yielded supportive immunologic responses coupled with extension of median and long-term survival in an unselected, intermediate and poor risk prognosis mRCC population. # NCT00678119
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

  • Education
  • Science
  • Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We're unsure how the site profits.

Not every website is profit-driven; some are created to spread information or serve as an online presence. Websites can be made for many reasons. This could be one of them. Link.springer.com might be making money, but it's not detectable how they're doing it.

Keywords {🔍}

patients, ags, pubmed, sunitinib, study, article, risk, cell, google, scholar, survival, cells, treatment, cas, cancer, response, renal, intermediate, tumor, clinical, carcinoma, poor, mrcc, immunotherapy, metastatic, months, ctls, therapy, rcc, phase, number, events, immune, time, rna, responses, median, dose, autologous, targeted, analysis, dcs, patient, prior, central, clin, data, dendritic, combination, adverse,

Topics {✒️}

multi-color flow cytometry metastatic renal-cell carcinoma functional cd28+/cd45ra- ctls/ml rna encoding cd40l tumor antigen-specific stimulating cell-mediated immunity myeloid cell-mediated immunosuppression full size image matured monocyte-derived dcs patient-specific tumor antigens renal cell carcinoma functional cd28+/cd45ra- ctls cd8+ t-cell memory article download pdf cd8 t-cell population myeloid-derived suppressor cells patient-specific immunotherapeutic product rna-loaded mature dcs therapy-specific response criteria track t-cell proliferation rna-transfected dendritic cells /1 μg/ml prostaglandin e2 motzer rj cytotoxic t-cell responses cr + pr + stable disease [sd] renal cell cancer anti-angiogenic agent combined identify cd28+/cd45ra- cd8 + localized injection-site reactions tumor-reactive ctls prior early-stage colorectal cancer vaccine-mediated antitumor immunity clear cell mrcc generate anti-tumor memory multiplex rt-pcr amplification tumor micro-environment observed kaplan-meier pfs estimates mild injection-site reactions dendritic-cell immunotherapy decreases t-regulatory cells open access license vascular endothelial growth small number multiple target antigens frequent ags-003-related events autologous tumor rna effector memory ctls kaplan-meier os estimates published randomised trials induced ctl response

Questions {❓}

  • Memory T cells in cancer immunotherapy: which CD8 T-cell population provides the best protection against tumours?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Survival with AGS-003, an autologous dendritic cell–based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results
         description:AGS-003 is an autologous immunotherapy prepared from fully matured and optimized monocyte-derived dendritic cells, which are co-electroporated with amplified tumor RNA plus synthetic CD40L RNA. AGS-003 was evaluated in combination with sunitinib in an open label phase 2 study in intermediate and poor risk, treatment naïve patients with metastatic clear cell renal cell carcinoma (mRCC). Twenty-one intermediate and poor risk patients were treated continuously with sunitinib (4 weeks on, 2 weeks off per 6 week cycle). After completion of the first cycle of sunitinib, patients were treated with AGS-003 every 3 weeks for 5 doses, then every 12 weeks until progression or end of study. The primary endpoint was to determine the complete response rate. Secondary endpoints included clinical benefit, safety, progression free survival (PFS) and overall survival (OS). Immunologic response was also monitored. Thirteen patients (62%) experienced clinical benefit (9 partial responses, 4 with stable disease); however there were no complete responses in this group of intermediate and poor risk mRCC patients and enrollment was terminated early. Median PFS from registration was 11.2 months (95% CI 6.0, 19.4) and the median OS from registration was 30.2 months (95% CI 9.4, 57.1) for all patients. Seven (33%) patients survived for at least 4.5 years, while five (24%) survived for more than 5 years, including 2 patients who remain progression-free with durable responses for more than 5 years at the time of this report. AGS-003 was well tolerated with only mild injection-site reactions. The most common adverse events were related to expected toxicity from sunitinib therapy. In patients who had sequential samples available for immune monitoring, the magnitude of the increase in the absolute number of CD8+ CD28+ CD45RA− effector/memory T cells (CTLs) after 5 doses of AGS-003 relative to baseline, correlated with overall survival. AGS-003 in combination with sunitinib was well tolerated and yielded supportive immunologic responses coupled with extension of median and long-term survival in an unselected, intermediate and poor risk prognosis mRCC population. # NCT00678119
         datePublished:2015-04-21T00:00:00Z
         dateModified:2015-04-21T00:00:00Z
         pageStart:1
         pageEnd:13
         license:http://creativecommons.org/publicdomain/zero/1.0/
         sameAs:https://doi.org/10.1186/s40425-015-0055-3
         keywords:
            Immunotherapy
            Dendritic cell
            RCC
            AGS-003
            Sunitinib
            Oncology
            Immunology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs40425-015-0055-3/MediaObjects/40425_2015_55_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs40425-015-0055-3/MediaObjects/40425_2015_55_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs40425-015-0055-3/MediaObjects/40425_2015_55_Fig3_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs40425-015-0055-3/MediaObjects/40425_2015_55_Fig4_HTML.gif
         isPartOf:
            name:Journal for ImmunoTherapy of Cancer
            issn:
               2051-1426
            volumeNumber:3
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Asim Amin
               affiliation:
                     name:Levine Cancer Institute
                     address:
                        name:Levine Cancer Institute, Charlotte, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Arkadiusz Z Dudek
               affiliation:
                     name:University of Illinois Cancer Center
                     address:
                        name:University of Illinois Cancer Center, Chicago, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Theodore F Logan
               affiliation:
                     name:Indiana University Simon Cancer Center
                     address:
                        name:Indiana University Simon Cancer Center, Indianapolis, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Raymond S Lance
               affiliation:
                     name:Urology of Virginia
                     address:
                        name:Urology of Virginia, Norfolk, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jeffrey M Holzbeierlein
               affiliation:
                     name:University of Kansas Medical Center
                     address:
                        name:University of Kansas Medical Center, Kansas City, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jennifer J Knox
               affiliation:
                     name:Princess Margaret Hospital
                     address:
                        name:Princess Margaret Hospital, Toronto, Canada
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Viraj A Master
               affiliation:
                     name:Emory University
                     address:
                        name:Emory University, Atlanta, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Sumanta K Pal
               affiliation:
                     name:City of Hope Comprehensive Cancer Center
                     address:
                        name:City of Hope Comprehensive Cancer Center, Duarte, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Wilson H Miller
               affiliation:
                     name:Lady Davis Institute and Segal Cancer Center-Jewish General Hospital, McGill University
                     address:
                        name:Lady Davis Institute and Segal Cancer Center-Jewish General Hospital, McGill University, Montreal, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Lawrence I Karsh
               affiliation:
                     name:The Urology Center of Colorado
                     address:
                        name:The Urology Center of Colorado, Denver, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Irina Y Tcherepanova
               affiliation:
                     name:Argos Therapeutics, Inc.
                     address:
                        name:Argos Therapeutics, Inc., Durham, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Mark A DeBenedette
               affiliation:
                     name:Argos Therapeutics, Inc.
                     address:
                        name:Argos Therapeutics, Inc., Durham, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:W Lee Williams
               affiliation:
                     name:Argos Therapeutics, Inc.
                     address:
                        name:Argos Therapeutics, Inc., Durham, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Douglas C Plessinger
               affiliation:
                     name:Argos Therapeutics, Inc.
                     address:
                        name:Argos Therapeutics, Inc., Durham, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Charles A Nicolette
               affiliation:
                     name:Argos Therapeutics, Inc.
                     address:
                        name:Argos Therapeutics, Inc., Durham, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Robert A Figlin
               affiliation:
                     name:Cedars-Sinai Medical Center
                     address:
                        name:Cedars-Sinai Medical Center, Los Angeles, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Survival with AGS-003, an autologous dendritic cell–based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results
      description:AGS-003 is an autologous immunotherapy prepared from fully matured and optimized monocyte-derived dendritic cells, which are co-electroporated with amplified tumor RNA plus synthetic CD40L RNA. AGS-003 was evaluated in combination with sunitinib in an open label phase 2 study in intermediate and poor risk, treatment naïve patients with metastatic clear cell renal cell carcinoma (mRCC). Twenty-one intermediate and poor risk patients were treated continuously with sunitinib (4 weeks on, 2 weeks off per 6 week cycle). After completion of the first cycle of sunitinib, patients were treated with AGS-003 every 3 weeks for 5 doses, then every 12 weeks until progression or end of study. The primary endpoint was to determine the complete response rate. Secondary endpoints included clinical benefit, safety, progression free survival (PFS) and overall survival (OS). Immunologic response was also monitored. Thirteen patients (62%) experienced clinical benefit (9 partial responses, 4 with stable disease); however there were no complete responses in this group of intermediate and poor risk mRCC patients and enrollment was terminated early. Median PFS from registration was 11.2 months (95% CI 6.0, 19.4) and the median OS from registration was 30.2 months (95% CI 9.4, 57.1) for all patients. Seven (33%) patients survived for at least 4.5 years, while five (24%) survived for more than 5 years, including 2 patients who remain progression-free with durable responses for more than 5 years at the time of this report. AGS-003 was well tolerated with only mild injection-site reactions. The most common adverse events were related to expected toxicity from sunitinib therapy. In patients who had sequential samples available for immune monitoring, the magnitude of the increase in the absolute number of CD8+ CD28+ CD45RA− effector/memory T cells (CTLs) after 5 doses of AGS-003 relative to baseline, correlated with overall survival. AGS-003 in combination with sunitinib was well tolerated and yielded supportive immunologic responses coupled with extension of median and long-term survival in an unselected, intermediate and poor risk prognosis mRCC population. # NCT00678119
      datePublished:2015-04-21T00:00:00Z
      dateModified:2015-04-21T00:00:00Z
      pageStart:1
      pageEnd:13
      license:http://creativecommons.org/publicdomain/zero/1.0/
      sameAs:https://doi.org/10.1186/s40425-015-0055-3
      keywords:
         Immunotherapy
         Dendritic cell
         RCC
         AGS-003
         Sunitinib
         Oncology
         Immunology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs40425-015-0055-3/MediaObjects/40425_2015_55_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs40425-015-0055-3/MediaObjects/40425_2015_55_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs40425-015-0055-3/MediaObjects/40425_2015_55_Fig3_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs40425-015-0055-3/MediaObjects/40425_2015_55_Fig4_HTML.gif
      isPartOf:
         name:Journal for ImmunoTherapy of Cancer
         issn:
            2051-1426
         volumeNumber:3
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Asim Amin
            affiliation:
                  name:Levine Cancer Institute
                  address:
                     name:Levine Cancer Institute, Charlotte, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Arkadiusz Z Dudek
            affiliation:
                  name:University of Illinois Cancer Center
                  address:
                     name:University of Illinois Cancer Center, Chicago, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Theodore F Logan
            affiliation:
                  name:Indiana University Simon Cancer Center
                  address:
                     name:Indiana University Simon Cancer Center, Indianapolis, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Raymond S Lance
            affiliation:
                  name:Urology of Virginia
                  address:
                     name:Urology of Virginia, Norfolk, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jeffrey M Holzbeierlein
            affiliation:
                  name:University of Kansas Medical Center
                  address:
                     name:University of Kansas Medical Center, Kansas City, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jennifer J Knox
            affiliation:
                  name:Princess Margaret Hospital
                  address:
                     name:Princess Margaret Hospital, Toronto, Canada
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Viraj A Master
            affiliation:
                  name:Emory University
                  address:
                     name:Emory University, Atlanta, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Sumanta K Pal
            affiliation:
                  name:City of Hope Comprehensive Cancer Center
                  address:
                     name:City of Hope Comprehensive Cancer Center, Duarte, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Wilson H Miller
            affiliation:
                  name:Lady Davis Institute and Segal Cancer Center-Jewish General Hospital, McGill University
                  address:
                     name:Lady Davis Institute and Segal Cancer Center-Jewish General Hospital, McGill University, Montreal, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Lawrence I Karsh
            affiliation:
                  name:The Urology Center of Colorado
                  address:
                     name:The Urology Center of Colorado, Denver, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Irina Y Tcherepanova
            affiliation:
                  name:Argos Therapeutics, Inc.
                  address:
                     name:Argos Therapeutics, Inc., Durham, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Mark A DeBenedette
            affiliation:
                  name:Argos Therapeutics, Inc.
                  address:
                     name:Argos Therapeutics, Inc., Durham, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:W Lee Williams
            affiliation:
                  name:Argos Therapeutics, Inc.
                  address:
                     name:Argos Therapeutics, Inc., Durham, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Douglas C Plessinger
            affiliation:
                  name:Argos Therapeutics, Inc.
                  address:
                     name:Argos Therapeutics, Inc., Durham, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Charles A Nicolette
            affiliation:
                  name:Argos Therapeutics, Inc.
                  address:
                     name:Argos Therapeutics, Inc., Durham, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Robert A Figlin
            affiliation:
                  name:Cedars-Sinai Medical Center
                  address:
                     name:Cedars-Sinai Medical Center, Los Angeles, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Journal for ImmunoTherapy of Cancer
      issn:
         2051-1426
      volumeNumber:3
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Levine Cancer Institute
      address:
         name:Levine Cancer Institute, Charlotte, USA
         type:PostalAddress
      name:University of Illinois Cancer Center
      address:
         name:University of Illinois Cancer Center, Chicago, USA
         type:PostalAddress
      name:Indiana University Simon Cancer Center
      address:
         name:Indiana University Simon Cancer Center, Indianapolis, USA
         type:PostalAddress
      name:Urology of Virginia
      address:
         name:Urology of Virginia, Norfolk, USA
         type:PostalAddress
      name:University of Kansas Medical Center
      address:
         name:University of Kansas Medical Center, Kansas City, USA
         type:PostalAddress
      name:Princess Margaret Hospital
      address:
         name:Princess Margaret Hospital, Toronto, Canada
         type:PostalAddress
      name:Emory University
      address:
         name:Emory University, Atlanta, USA
         type:PostalAddress
      name:City of Hope Comprehensive Cancer Center
      address:
         name:City of Hope Comprehensive Cancer Center, Duarte, USA
         type:PostalAddress
      name:Lady Davis Institute and Segal Cancer Center-Jewish General Hospital, McGill University
      address:
         name:Lady Davis Institute and Segal Cancer Center-Jewish General Hospital, McGill University, Montreal, USA
         type:PostalAddress
      name:The Urology Center of Colorado
      address:
         name:The Urology Center of Colorado, Denver, USA
         type:PostalAddress
      name:Argos Therapeutics, Inc.
      address:
         name:Argos Therapeutics, Inc., Durham, USA
         type:PostalAddress
      name:Argos Therapeutics, Inc.
      address:
         name:Argos Therapeutics, Inc., Durham, USA
         type:PostalAddress
      name:Argos Therapeutics, Inc.
      address:
         name:Argos Therapeutics, Inc., Durham, USA
         type:PostalAddress
      name:Argos Therapeutics, Inc.
      address:
         name:Argos Therapeutics, Inc., Durham, USA
         type:PostalAddress
      name:Argos Therapeutics, Inc.
      address:
         name:Argos Therapeutics, Inc., Durham, USA
         type:PostalAddress
      name:Cedars-Sinai Medical Center
      address:
         name:Cedars-Sinai Medical Center, Los Angeles, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Asim Amin
      affiliation:
            name:Levine Cancer Institute
            address:
               name:Levine Cancer Institute, Charlotte, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Arkadiusz Z Dudek
      affiliation:
            name:University of Illinois Cancer Center
            address:
               name:University of Illinois Cancer Center, Chicago, USA
               type:PostalAddress
            type:Organization
      name:Theodore F Logan
      affiliation:
            name:Indiana University Simon Cancer Center
            address:
               name:Indiana University Simon Cancer Center, Indianapolis, USA
               type:PostalAddress
            type:Organization
      name:Raymond S Lance
      affiliation:
            name:Urology of Virginia
            address:
               name:Urology of Virginia, Norfolk, USA
               type:PostalAddress
            type:Organization
      name:Jeffrey M Holzbeierlein
      affiliation:
            name:University of Kansas Medical Center
            address:
               name:University of Kansas Medical Center, Kansas City, USA
               type:PostalAddress
            type:Organization
      name:Jennifer J Knox
      affiliation:
            name:Princess Margaret Hospital
            address:
               name:Princess Margaret Hospital, Toronto, Canada
               type:PostalAddress
            type:Organization
      name:Viraj A Master
      affiliation:
            name:Emory University
            address:
               name:Emory University, Atlanta, USA
               type:PostalAddress
            type:Organization
      name:Sumanta K Pal
      affiliation:
            name:City of Hope Comprehensive Cancer Center
            address:
               name:City of Hope Comprehensive Cancer Center, Duarte, USA
               type:PostalAddress
            type:Organization
      name:Wilson H Miller
      affiliation:
            name:Lady Davis Institute and Segal Cancer Center-Jewish General Hospital, McGill University
            address:
               name:Lady Davis Institute and Segal Cancer Center-Jewish General Hospital, McGill University, Montreal, USA
               type:PostalAddress
            type:Organization
      name:Lawrence I Karsh
      affiliation:
            name:The Urology Center of Colorado
            address:
               name:The Urology Center of Colorado, Denver, USA
               type:PostalAddress
            type:Organization
      name:Irina Y Tcherepanova
      affiliation:
            name:Argos Therapeutics, Inc.
            address:
               name:Argos Therapeutics, Inc., Durham, USA
               type:PostalAddress
            type:Organization
      name:Mark A DeBenedette
      affiliation:
            name:Argos Therapeutics, Inc.
            address:
               name:Argos Therapeutics, Inc., Durham, USA
               type:PostalAddress
            type:Organization
      name:W Lee Williams
      affiliation:
            name:Argos Therapeutics, Inc.
            address:
               name:Argos Therapeutics, Inc., Durham, USA
               type:PostalAddress
            type:Organization
      name:Douglas C Plessinger
      affiliation:
            name:Argos Therapeutics, Inc.
            address:
               name:Argos Therapeutics, Inc., Durham, USA
               type:PostalAddress
            type:Organization
      name:Charles A Nicolette
      affiliation:
            name:Argos Therapeutics, Inc.
            address:
               name:Argos Therapeutics, Inc., Durham, USA
               type:PostalAddress
            type:Organization
      name:Robert A Figlin
      affiliation:
            name:Cedars-Sinai Medical Center
            address:
               name:Cedars-Sinai Medical Center, Los Angeles, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Levine Cancer Institute, Charlotte, USA
      name:University of Illinois Cancer Center, Chicago, USA
      name:Indiana University Simon Cancer Center, Indianapolis, USA
      name:Urology of Virginia, Norfolk, USA
      name:University of Kansas Medical Center, Kansas City, USA
      name:Princess Margaret Hospital, Toronto, Canada
      name:Emory University, Atlanta, USA
      name:City of Hope Comprehensive Cancer Center, Duarte, USA
      name:Lady Davis Institute and Segal Cancer Center-Jewish General Hospital, McGill University, Montreal, USA
      name:The Urology Center of Colorado, Denver, USA
      name:Argos Therapeutics, Inc., Durham, USA
      name:Argos Therapeutics, Inc., Durham, USA
      name:Argos Therapeutics, Inc., Durham, USA
      name:Argos Therapeutics, Inc., Durham, USA
      name:Argos Therapeutics, Inc., Durham, USA
      name:Cedars-Sinai Medical Center, Los Angeles, USA

External Links {🔗}(201)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Clipboard.js
  • Prism.js

CDN Services {📦}

  • Crossref

6.76s.